老年原发免疫性血小板减少症患者的治疗现状被引量：5

Current status of treatment for elderly patients with immune thrombocytopenia

导出

摘要原发免疫性血小板减少症（immune thrombocytopenia,ITP）,既往称特发性血小板减少性紫癜,自身免疫性血小板减少性紫癜,是血小板破坏过多和血小板生成相对不足双重打击下的自身免疫性疾病。成人ITP发病率为（5～10）/10万[1],男女发病率相近。几项大型的流行病学研究表明,ITP的发病率随年龄的增加而增加,并且在老年患者中,女性比男性更易受影响[2]。 With the prolongation of life,immune thrombocytopenia（ITP）is becoming more and more frequent in the elderly.At present,the research object of ITP is mainly aimed at children and adults,and there is less research on the elderly.The therapeutic strategy differs from that for younger patients and must consider the greater risk of bleeding and thrombosis,poor life expectancy and concomitant medications.This review summarizes the current status of treatment for elderly patients with ITP.

作者王孟林王巍

机构地区哈尔滨医科大学第二附属医院血液内科

出处《临床血液学杂志》 CAS 2018年第3期398-401,共4页 Journal of Clinical Hematology

关键词免疫性血小板减少症老年人利妥昔单抗促血小板生成药物脾切除 immune thrombocytopenia elderly rituximab platelet stimulating agent splenectomy

分类号 R558.2 [医药卫生—血液循环系统疾病]

引文网络
相关文献

参考文献3

1Héctor Eloy Tamez-Pérez,Dania Lizet Quintanilla-Flores,René Rodríguez-Gutiérrez,José Gerardo González-González,Alejandra Lorena Tamez-Pena.Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review[J].World Journal of Diabetes,2015,6(8):1073-1081. 被引量：16
2侯明,秦平.成人原发免疫性血小板减少症诊治的中国专家共识(2016版)解读[J].临床血液学杂志,2016,29(4):523-527. 被引量：89
3刘隽,程毅敏,邹丽芳,汪蕾,姚一芸,唐勇,庄衍,励菁菁,朱琦.重组人血小板生成素治疗老年慢性免疫性血小板减少性紫癜的疗效观察[J].中国临床医学,2013,20(3):390-392. 被引量：13

二级参考文献78

1赵永强,王庆余,翟明,徐健,陈协群,刘文励,张梅,宋善俊,王健民,孟凡义,单渊东.重组人血小板生成素治疗慢性难治性特发性血小板减少性紫癜的多中心临床试验[J].中华内科杂志,2004,43(8):608-610. 被引量：102
2Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpnra in the general practice re search database[J]. Br J Haematol, 2009, 145(2) : 235-244.
3中华医学会血液学分会血栓与止血学组.成人ITP诊治的中国专家共识(修订版)[J].中华血液学杂志,2011,32(3):218-219.
4yon dem Borne A, Folman C, van den Oudenrijn S, et al. The potential role of thrombopoietin in idiopathic thrombocytopenic purpura[J]. Blood Rev, 2002, 16(1), 57-59.
5Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies [J]. Blood, 2002, 100(10) : 3457 3469.
6Trence DL. Management of patients on chronic glucocorticoidtherapy: an endocrine perspective. Prim Care 2003; 30: 593-605#[PMID: 14692203 DOI: 10.1016/s0095-4543(03)00038-1].
7Tamez Perez HE, Gómez de Ossio MD, Quintanilla Flores DL,Hernández Coria MI, Tamez Pe-a AL, Cuz Pérez GJ, ProskauerPe-a SL. Glucose disturbances in non-diabetic patients receivingacute treatment with methylprednisolone pulses. Rev AssocMed Bras 2012; 58: 125-128 [PMID: 22392327 DOI: 10.1016/s0104-4230(12)70165-3].
8Ha Y, Lee KH, Jung S, Lee SW, Lee SK, Park YB. Glucocorticoidinduceddiabetes mellitus in patients with systemic lupuserythematosus treated with high-dose glucocorticoid therapy. Lupus2011; 20: 1027-1034 [PMID: 21659423 DOI: 10.1177/0961203311402246].
9van Raalte DH, Ouwens DM, Diamant M. Novel insights intoglucocorticoid-mediated diabetogenic effects: towards expansionof therapeutic options- Eur J Clin Invest 2009; 39: 81-93 [PMID:19200161 DOI: 10.1111/j.1365-2362.2008.02067].
10Sch-cke H, D-cke WD, Asadullah K. Mechanisms involved in theside effects of glucocorticoids. Pharmacol Ther 2002; 96: 23-43[PMID: 12441176 DOI: 10.1016/s0163-7258(02)00297-8].